ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Recruiting
Sponsor: Psoriasis Treatment Center of Central New Jersey
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Research Team
Eligibility Criteria
Inclusion Criteria
Male or female adult ≥ 18 years of age;
Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
BSA 10%
See 4 more
Treatment Details
Interventions
- Ilumya Injectable Product (Monoclonal Antibodies)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: IlumyaExperimental Treatment1 Intervention
Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Psoriasis Treatment Center of Central New JerseyEast Windsor, NJ
Loading ...
Who Is Running the Clinical Trial?
Psoriasis Treatment Center of Central New Jersey
Lead Sponsor
Trials
18
Recruited
530+
Sun Pharmaceutical Industries Limited
Industry Sponsor
Trials
71
Recruited
14,000+
Dilip Shanghvi
Sun Pharmaceutical Industries Limited
Chief Executive Officer since 1993
Majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor
Dr. Azadar H. Khan
Sun Pharmaceutical Industries Limited
Chief Medical Officer since 2023
MD from a recognized institution